Where others have failed will Atl1102 succeed ?, page-595

Reviewing Sarepta's prospectus supporting the US$500m a couple of key points are mentioned in the forward looking statement section:
- our plan to expand our pipeline through internal research and development and through strategic transactions;
- our plan to evaluate future engagement with the European Medicines Agency on potential next steps for EMA approval of our products;

- our ability to further secure long-term supply of our commercial products and our product candidates to satisfy our planned commercial,
early access programs and clinical needs;

All sounds very familiar